New yellow fever vaccine shows promise in early safety trial
NCT ID NCT05172544
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 1 trial tested an inactivated yellow fever vaccine called HydroVax-002 YFV in 26 healthy adults. Participants received two doses of either the vaccine or a placebo. The main goal was to check safety and side effects, while also measuring immune response. The trial is complete, but results are not yet public.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HydroVax-002 YFV (inactivated yellow fever virus vaccine)
What this could lead to
If successful, this could lead to a safer yellow fever vaccine, especially for people who cannot receive the current live vaccine.
What could go wrong
This is an early Phase 1 trial with only 26 people, so it is too soon to know if the vaccine will work in larger populations or be widely approved.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for YELLOW FEVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University Health System
Durham, North Carolina, 27705, United States